Jean Charcot Seabeam Survey along ODP Leg 112 Northern Transect

A marine geophysical survey that used Seabeam, multi- and single-channel seismic reflection, gravity, and magnetic profiling was conducted in two locations along the landward slope of the Peru Trench. This survey was conducted during the SeaPERC cruise of the Jean Charcot in July 1986 (Bourgois et al., 1986a; Bourgois et al., 1986b; Bourgois et al., 1987; Bourgois et al., in press). These areas were two possible drilling locations for ODP Leg 112, which was scheduled to begin in November 1986. The drilling transects center around latitudes of 5°30'S and 9°30'S, along multichannel seismic lines CDP-3 and CDP-2, respectively. The northern transect is located in the Paita Zone (Fig. 1, Box 2), and the southern transect is in the Chimbote Zone (Fig. 1, Box 6). During Leg 112, we drilled two sites (683 and 685) in the Chimbote area. This became the northern transect of Leg 112. Here, we report the Seabeam data acquired during the SeaPERC cruise. Drilling results from Sites 683 and 685, the CDP-2 multichannel seismic record, and the Seabeam data provide a threedimensional view of this region

Seabeam and seismic reflection imaging of the tectonic regime of the Andean continental margin off Peru (4°S to 10°S)

Suite à une campagne géophysique réalisée au large de la côte du Perou (croisière Seaperc du R/V "Jean Charcot", juillet 1986), les auteurs proposent une nouvelle interprétation des structures caractérisant la pente continentale de la région étudiée. D'autre part, ils considèrent que cette marge active est une marge active en extension ou bien une marge d'effondrement qui développe un complexe d'accrétion induit par les effondrements de la partie médiane de la pente

European society of urogenital radiology (ESUR) guidelines: MR imaging of pelvic endometriosis

Endometriosis is a common gynaecological condition of unknown aetiology that primarily affects women of reproductive age. The accepted first-line imaging modality is pelvic ultrasound. However, magnetic resonance imaging (MRI) is increasingly performed as an additional investigation in complex cases and for surgical planning. There is currently no international consensus regarding patient preparation, MRI protocols or reporting criteria. Our aim was to develop clinical guidelines for MRI evaluation of pelvic endometriosis based on literature evidence and consensus expert opinion. This work was performed by a group of radiologists from the European Society of Urogenital Radiology (ESUR), experts in gynaecological imaging and a gynaecologist expert in methodology. The group discussed indications for MRI, technical requirements, patient preparation, MRI protocols and criteria for the diagnosis of pelvic endometriosis on MRI. The expert panel proposed a final recommendation for each criterion using Oxford Centre for Evidence Based Medicine (OCEBM) 2011 levels of evidence.info:eu-repo/semantics/publishedVersio

Expansion of elevational range in a forest pest: Can parasitoids track their hosts?

We are thankful to Karim Senhadji and Ramon Ruiz-Puche for their help during the field work, and to Sara Garcia Morato for her contribution to quantifying rates of parasitism in PPM clutches at the laboratory. Two anonymous referees contributed to improve the manuscript. This study was supported by projects PROPINOL (PN22/2008), GESBOME (P06-RNM-1890) from Junta de Andalucia, REMEDINAL TE-CM (S2018/EMT-4338) from Comunidad de Madrid, ADAPTAMED (LIFE14 CCA/ES/000612) from LIFE program, and GILES (PCIN-2016-150) from the ERANET-LAC H2020 Programme.Gradients in elevation impose changes in environmental conditions, which in turn modulate species distribution and abundance as well as the interactions they maintain. Along the gradient, interacting species (e.g., predators, parasitoids) can respond to changes in different ways. This study aims to investigate how egg parasitism of a forest pest, the pine processionary moth (PPM), Thaumetopoea pityocampa, vary along an elevational gradient (190-2000 m.a.s.l.) in a mountain range of SE Spain, including areas of recent elevational expansion, for a seven years period (2008-2014). We used generalized linear mixed models to ascertain the effect of both elevation and the winter North Atlantic Oscillation (NAO) index (a proxy of interannual climatic conditions) on the rate of parasitism, and the occurrence probabilities of two parasitoid species: a PPM specialist and a generalist species. Since four pine species are stratified along the elevational gradient, we repeated all the analyses separately for lowlands (190-1300 m. a.s.l.) and uplands (1350-2000 m. a.s.l.). Results showed a decrease in both parasitism rate and probability of occurrence of the two main parasitoid species with elevation, although decline was more severe for the specialist species. The effect of elevation was more conspicuous and intense in uplands than in lowlands. Positive NAO winter values, associated with cold and dry winters, reduced the rate of parasitism and the probability of occurrence of the two main parasitoid species-but particularly for the generalist species-as elevation increases. In a context of climate warming, it is crucial to mitigate PPM elevational and latitudinal expansion. Increasing tree diversity at the PPM expansion areas may favor the establishment of parasitoids, which could contribute to synchronizing host- parasitoid interactions and minimize the risk of PPM outbreaks.Junta de Andalucia PN22/2008REMEDINAL TE-CM from Comunidad de Madrid S2018/EMT-4338ADAPTAMED from LIFE program LIFE14 CCA/ES/000612GILES from the ERANET-LAC H2020 Programme PCIN-2016-150Junta de Andalucia P06-RNM-189

Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study

<p>Abstract</p> <p>Background</p> <p>The inhaled corticosteroid (ICS) fluticasone propionate (fluticasone) and the long-acting β₂-agonist (LABA) formoterol fumarate (formoterol) are being made available as a combination product (fluticasone/formoterol, <b><it>flutiform</it></b>^®) in a single aerosol inhaler. This 12-week, open-label, randomized, active-controlled, parallel-group, multicentre, phase 3 study compared the efficacy and safety of fluticasone/formoterol with the commercially available combination product fluticasone/salmeterol.</p> <p>Methods</p> <p>Patients aged ≥ 18 years (N = 202) with mild-to-moderate–severe, persistent asthma for ≥ 6 months prior to screening were included in the study. After a screening phase (4–10 days), eligible patients were randomized 1:1 to receive fluticasone/formoterol or fluticasone/salmeterol during the 12-week treatment period. The primary objective was to demonstrate non-inferiority of fluticasone/formoterol versus fluticasone/salmeterol, measured by pre-dose forced expiratory volume in the first second (FEV₁), at week 12.</p> <p>Results</p> <p>Fluticasone/formoterol was comparable to fluticasone/salmeterol for the primary efficacy endpoint, mean pre-dose FEV₁at week 12. The new combination was also comparable to fluticasone/salmeterol for change from baseline to week 12 in pre-dose FEV₁, change from pre-dose FEV₁at baseline to 2-hour post-dose FEV₁at week 12 and discontinuations due to lack of efficacy. Importantly, fluticasone/formoterol was superior to fluticasone/salmeterol in time to onset of action throughout the duration of the study. The two treatments demonstrated similar results for various other secondary efficacy parameters, including other lung function tests, patient-reported outcomes, rescue medication use, asthma exacerbations and Asthma Quality of Life Questionnaire scores. Fluticasone/formoterol was well tolerated and had a good safety profile that was similar to fluticasone/salmeterol.</p> <p>Conclusions</p> <p>The results of this study indicate that fluticasone/formoterol is as effective as fluticasone/salmeterol, and has a more rapid onset of action, reflecting the faster bronchodilatory effects of formoterol compared with those of salmeterol. If patients perceive the benefits of therapy with fluticasone/formoterol more rapidly than with fluticasone/salmeterol, this could have a positive impact on preference and adherence.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov: <a href="http://www.clinicaltrials.gov/ct2/show/NCT00476073">NCT00476073</a></p

Hystricognathy vs Sciurognathy in the Rodent Jaw: A New Morphometric Assessment of Hystricognathy Applied to the Living Fossil Laonastes (Diatomyidae)

While exceptional for an intense diversification of lineages, the evolutionary history of the order Rodentia comprises only a limited number of morphological morphotypes for the mandible. This situation could partly explain the intense debates about the taxonomic position of the latest described member of this clade, the Laotian rock rat Laonastes aenigmamus (Diatomyidae). This discovery has re-launched the debate on the definition of the Hystricognathi suborder identified using the angle of the jaw relative to the plane of the incisors. Our study aims to end this ambiguity. For clarity, it became necessary to revisit the entire morphological diversity of the mandible in extant and extinct rodents. However, current and past rodent diversity brings out the limitations of the qualitative descriptive approach and highlights the need for a quantitative approach. Here, we present the first descriptive comparison of the masticatory apparatus within the Ctenohystrica clade, in combining classic comparative anatomy with morphometrical methods. First, we quantified the shape of the mandible in rodents using 3D landmarks. Then, the analysis of osteological features was compared to myological features in order to understand the biomechanical origin of this morphological diversity. Among the morphological variation observed, the mandible of Laonastes aenigmamus displays an intermediate association of features that could be considered neither as sciurognathous nor as hystricognathous

Antibiotics for coughing in general practice: a questionnaire study to quantify and condense the reasons for prescribing

BACKGROUND: Antibiotics are being overprescribed in ambulant care, especially for respiratory tract infections (RTIs). Gaining insight into the actual reasons for prescribing remains important for the design of effective strategies to optimise antibiotic prescribing. We aimed to determine items of importance for the antibiotic prescribing decision and to make them operational for an intervention trial. METHODS: A postal questionnaire based upon focus group findings was sent to 316 Flemish general practitioners (GPs). On a verbal rating scale the GPs scored to what extent they consider the questionnaire items in decision making in case of suspected RTI in a coughing patient and how strongly the items support or counter antibiotic treatment. Factor analysis was used to condense the data. The relative importance of the yielded operational factors was assessed using Wilcoxon Matched Pairs test. RESULTS: 59.5% completed the study. Response group characteristics (mean age: 42.8 years; 65.9% men) approximated that of all Flemish GPs. Participants considered all the items included in the questionnaire: always the operational factor 'lung auscultation', often 'whether or not there is something unusual happening' – both medical reasons – and to a lesser extent 'non-medical reasons' (P < 0.001). Non-medical as well as medical reasons support antibiotic treatment, but non-medical reasons to a lesser extent (P < 0.001). CONCLUSION: This study quantified, condensed and confirmed the findings of previous focus group research. Practice guidelines and interventions to optimise antibiotic prescribing have to take non-medical reasons into account

Can oral corticosteroids reduce the severity or duration of an acute cough, and the associated National Health Service and societal costs, in adults presenting to primary care?: study protocol for a randomised controlled trial

Background: Acute lower respiratory tract infection (LRTI) is one of the most common conditions managed internationally and is costly to health services and patients. Despite good evidence that antibiotics are not effective for improving the symptoms of uncomplicated LRTI, they are widely prescribed, contributing to antimicrobial resistance. Many of the symptoms observed in LRTI are mediated by inflammatory processes also observed in exacerbations of asthma, for which there is strong evidence of corticosteroid effectiveness. The primary aim of the OSAC (Oral Steroids for Acute Cough) Trial is to determine whether oral prednisolone (40 mg daily for 5 days) can reduce the duration of moderately bad (or worse) cough and the severity of all its associated symptoms on days 2 to 4 post-randomisation (day 1 is trial entry) by at least 20% in adults ≥18 years with acute LRTI presenting to primary care. Methods/design: OSAC is a two-arm, multi-centre, placebo-controlled, randomised superiority trial. The target sample size is 436 patients, which allows for a 20% dropout rate. Patients will be recruited from primary care sites (General Practitioner surgeries) across England and followed up until symptom resolution. The two primary clinical outcomes are the duration of moderately bad (or worse) cough, and the severity of all its associated symptoms on days 2 to 4 post-randomisation. Secondary outcomes include: antibiotic consumption; symptom burden; adverse events; participant satisfaction with treatment and intention to consult for future similar illnesses. A parallel economic evaluation will investigate the cost-effectiveness of the intervention. Discussion: Results from the OSAC trial will increase knowledge regarding the clinical and cost-effectiveness of corticosteroids for LRTI, and will establish the potential of a new treatment option that could substantially improve patient health. We have chosen a relatively high ‘efficacy dose’ as this will enable us to decide on the potential for further research into lower dose oral and/or inhaled corticosteroids. This trial will also contribute to a growing body of research investigating the natural course of this very common illness, as well as the effects of steroids on the undesirable inflammatory symptoms associated with infection. Trial registration: Current Controlled Trials ISRCTN57309858 (31 January 2013)